Roche remains a Buy, driven by strong pipeline progress and conservative valuation, with shares up 36% since my last recommendation. CT388-103's Phase 2 obesity data show placebo-adjusted weight loss ...

A Roche obesity drug designed to hit two targets led to weight loss that is competitive with other drugs in its class, but from a development standpoint, the drug candidate still trails rival ...

Roche obesity drug shows 22.5% weight loss in Phase-II trial Roche focuses on catching Lilly in $150 billion obesity market Investors lukewarm on CT-388 results in crowded market The company said on ...

A property transfer from a Catholic organization to La Roche University sets the college up for long-term growth, officials say. The Sisters of Divine Providence has gifted the Providence Heights ...

Roche said its giredestrant drug reduced the risk of disease recurrence or death from breast cancer, suggesting potential for the medication to become standard-of-care when the disease is in the ...

Roche has rallied on improved sentiment around the late-stage pipeline, but near-term risk/reward is less compelling given elevated expectations and thin 2026 catalysts. The upcoming persevERA ...

Roche reported positive Phase III results on trials of its new multiple sclerosis (MS) drug today. Fenebrutinib appears effective at treating both relapsing multiple sclerosis and primary progressive ...

Roche Pharmaceuticals' CEO told investors she was "serious" about the goal of becoming a top 3 obesity player. The drugmaker's CT-388 weight loss injection is entering a phase III trial, marking the ...

Roche Holding AG will move an experimental obesity shot into late-stage trials next year in a bid to challenge leaders in the booming market for weight-loss medicines. The drug, known as CT-388, ...

Roche targets liver disease treatments with acquisition Deal includes $14.50 a share, potential milestone payments up to $6.00 a share Roche flags potential to treat obesity-related conditions The ...

Roche Holding AG is weighing direct-to-patient drug sales in the US, bypassing the middleman for its pricey medicines for multiple sclerosis, eye disease and cancer. The Swiss drugmaker has discussed ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — Roche is following its partner Sarepta Therapeutics and stopping ...